Hematopoietic Growth Factors Secreted by Seven Human Pleural Mesothelioma Cell Lines: Interleukin-6 Production as a Common Feature
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Seven mesothelioma cell lines, established from patients with pleural mesothelioma, exhibited substantial heterogeneity regarding in vitro morphology and growth characteristics. Media conditioned by these cell lines and by MeT5A normal mesothelial cells were examined for (i) colony formation on human bone-marrow cells, (ii) hematopoietic growth-factor content and (iii) mitogenic activity on mesothelioma cells. Colony-stimulating activity was produced only by the ZL34 cell line. Analysis of conditioned media by ELISA revealed that all mesothelioma cell lines constitutively produced IL-6, while the MeT5A normal mesothelial cells did not; in addition, GM-CSF and G-CSF were detected in the supernatant of the ZL34 cell line. Using a 3H-thymidine incorporation assay, we showed that all mesothelioma cell lines produced mitogenic activity in the culture supernatant, in contrast to the MeT5A normal mesothelial cells. The mitogenic effect of the hematopoietic growth factors detected in mesothelioma culture supernatants was tested on mesothelioma cells and on MeT5A normal mesothelial cells: IL-6, GM-CSF and G-CSF did not stimulate any DNA synthesis. Our results suggest that these hematopoietic growth factors do not act as autocrine growth factors. A common feature of this panel of mesothelioma cell lines is the production of IL-6; although the biological significance of the aberrant production of cytokines by mesotheliomas remains unclear, IL-6 might be involved in paraneoplastic syndromes such as thrombocytosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mesothelioma cells produce IL-6 [45,46]”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [46]
In the citing paper
“Mesothelioma cells produce IL-6 [45,46], and an elevation of the circulating level of IL-6 has been already described in mesothelioma patients, with this increase being associated with a negative clinical condition. High levels of IL-6 have been also revealed in patients’ pleural fluids [47].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [46]
Citations
Cites
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
Interleukin-6 is a potent thrombopoietic factor in vivo in mice
Ishibashi, T., Kimura, H., Shikama, Y., Uchida, T., Kariyone, S., Hirano, T., Kishimoto, T., Takatsuki, F., & Akiyama, Y. (1989) · Blood · doi:10.1182/blood.v74.4.1241.1241 · Cited by 432
Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomas
Miki, S., Iwano, M., Miki, Y., Yamamoto, M., Tang, B., Yokokawa, K., Sonoda, T., Hirano, T., & Kishimoto, T. (1989) · FEBS Letters · doi:10.1016/0014-5793(89)80805-1 · Cited by 411
Diffuse Malignant Mesothelioma: Prospective Evaluation of 69 Patients
CHAHINIAN, A. P., PAJAK, T. F., HOLLAND, J. F., NORTON, L., AMBINDER, R. M., & MANDEL, E. M. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-6-746 · Cited by 354
The Pathogenesis of Asbestos-Associated Diseases
Craighead, J. E., & Mossman, B. T. (1982) · New England Journal of Medicine · doi:10.1056/nejm198206173062403 · Cited by 333
Berdel, W., Danhauser-Riedl, S., Steinhauser, G., & Winton, E. (1989) · Blood · doi:10.1182/blood.v73.1.80.80 · Cited by 289
In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets
Asano, S., Okano, A., Ozawa, K., Nakahata, T., Ishibashi, T., Koike, K., Kimura, H., Tanioka, Y., Shibuya, A., & Hirano, T. (1990) · Blood · doi:10.1182/blood.v75.8.1602.1602 · Cited by 279
(1987) · Lung Cancer · doi:10.1016/s0169-5002(87)80408-7 · Cited by 263
Frei, K., Leist, T. P., Meager, A., Gallo, P., Leppert, D., Zinkernagel, R. M., & Fontana, A. (1988) · The Journal of experimental medicine · doi:10.1084/jem.168.1.449 · Cited by 245
Dedhar, S., Gaboury, L., Galloway, P., & Eaves, C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.23.9253 · Cited by 229
Research works printed but not linked: 1
- Lee J. D., 1991, Proceedings of the 82th annual meeting AACR. Houston, 228
Cited by
Interleukin-6 in Biology and Medicine
Akira, S., Taga, T., & Kishimoto, T. (1993) · Advances in Immunology · doi:10.1016/s0065-2776(08)60532-5 · Cited by 1,389
Malignant Pleural Mesothelioma
Tsao, A. S., Wistuba, I., Roth, J. A., & Kindler, H. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8523 · Cited by 481
Spatio‐temporally precise activation of engineered receptor tyrosine kinases by light
Grusch, M., Schelch, K., Riedler, R., Reichhart, E., Differ, C., Berger, W., Inglés‐Prieto, Á., & Janovjak, H. (2014) · The EMBO Journal · doi:10.15252/embj.201387695 · Cited by 245
“We first screened cells from different tumour entities for effects of FGF2, a prominent FGFR ligand, and we identified two cell lines derived from malignant pleural mesothelioma to be FGF2responsive (M38K and SPC212; Schmitter et al, 1992; Kahlos et al, 1998).”
BackgroundKroegel, C., & Antony, V. B. (1997) · European Respiratory Journal · doi:10.1183/09031936.97.10102411 · Cited by 232
“In addition to IL-8, a recent study showed that C5a may also contribute significantly to pleural accumulation of neutrophils following instillation of the streptococcal preparation OK-432 [ 3 ].”
BackgroundInfluentialImpact of pretreatment thrombocytosis on survival in primary breast cancer
Salat, A., Gnant, M., Kwasny, W., Mlineritsch, B., Menzel, R.-C., Schmid, M., Smola, M., Stierer, M., Tausch, C., Galid, A., et al. (2003) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613413 · Cited by 157
“One possible candidate is interleukin 6, since blood levels are reported to be high in malignant disease (36, 49, 50) and interleukin 6 is produced by various non-hematological cancer entities (51-55).”
BackgroundInterleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells
Schneider, M. R., Hoeflich, A., Fischer, J. R., Wolf, E., Sordat, B., & Lahm, H. (2000) · Cancer Letters · doi:10.1016/s0304-3835(99)00401-2 · Cited by 172
Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses
Hegmans, J. P. J. J., Hemmes, A., Hammad, H., Boon, L., Hoogsteden, H. C., & Lambrecht, B. N. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00135305 · Cited by 162
“IL-6 has also been shown by others to be universally expressed in MM cell lines [ 21 ].”
BackgroundFunctional inactivation of NF2/merlin in human mesothelioma
Thurneysen, C., Opitz, I., Kurtz, S., Weder, W., Stahel, R. A., & Felley‐Bosco, E. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.08.014 · Cited by 163
Self-citationHuman papillomavirus in a necessary cause of invasive cervical cancer worldwide
(1999) · Pure Amsterdam UMC · doi:10.1002/(sici)1096-9896(199909)189:1 · Cited by 140
Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin
Shi, Y., Felley-Bosco, E., Marti, T. M., Orlowski, K., Pruschy, M., & Stahel, R. A. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-571 · Cited by 124
“Human mesothelioma ZL55 [38], lung carcinoma A549 [39] cells, the colorectal carcinoma cell lines HCT116 40.”
Self-citationCharacteristics of nine newly derived mesothelioma cell lines
Pass, H. I., Stevens, E. J., Oie, H. K., Tsokos, M., Abati, A. D., Fetsch, P. A., Mew, D., Pogrebniak, H. W., & Matthews, W. J. (1995) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(95)00045-m · Cited by 130
“This repor t substant iates reports of high levels of IL-6 [13, 14] and GM-CSF [15] from body fluids or cell l ines of pat ients with mesothel ioma, and could explain part ial ly the dramatic elevations of platelet counts seen in pat ients with MPM.”
BackgroundBlum, W., Pecze, L., Wörthmüller, J., Steinauer, M., & Schwaller, B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4385-7 · Cited by 127
Nakano, T., Chahinian, A. P., Shinjyo, M., Tonomura, A., Miyake, M., Togawa, N., Ninomiya, K., & Higashino, K. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.150 · Cited by 122
Edwards, J. G., Swinson, D., Jones, J. L., Muller, S., Waller, D. A., & O'Byrne, K. J. (2003) · CHEST Journal · doi:10.1378/chest.124.5.1916 · Cited by 118
Circulating and Tumor-Infiltrating Myeloid Cells Predict Survival in Human Pleural Mesothelioma
Burt, B. M., Rodig, S. J., Tilleman, T. R., Elbardissi, A. W., Bueno, R., & Sugarbaker, D. J. (2011) · Cancer · doi:10.1002/cncr.26143 · Cited by 115
“Normal human mesothelial cells and established human MPM cell lines produce copious amounts of hematopoietic cytokines, including interleukin (IL)-6, IL8, macrophage inflammatory protein-1, granulocyte-colony stimulating factor, and granulocyte-macrophage-colony stimulating factor.(17,18) These cytokines provide chemo…”
BackgroundGAS5 long non-coding RNA in malignant pleural mesothelioma
Renganathan, A., Kresoja‐Rakic, J., Echeverry, N., Ziltener, G., Vrugt, B., Opitz, I., Stahel, R. A., & Felley‐Bosco, E. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-119 · Cited by 100
“MPM cells-SPC111, SPC212, ZL34 and ZL55, were established in our laboratory [50] and were maintained in DMEM:F12 (Ham) medium (Sigma-Aldrich, St.”
MethodSelf-citationEVALUATION OF TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN MALIGNANT MESOTHELIOMA
KUMAR-SINGH, S., VERMEULEN, P. B., WEYLER, J., SEGERS, K., WEYN, B., VAN DAELE, A., DIRIX, L. Y., VAN OOSTEROM, A. T., & VAN MARCK, E. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199706)182:2<211::aid-path834>3.0.co;2-d · Cited by 84
Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
Kirschner, M. B., Pulford, E., Hoda, M. A., Rózsás, A., Griggs, K. M., Cheng, Y. Y., Edelman, J. J., Kao, S., Hyland, R. A., Dong, Y., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.286 · Cited by 91
“The additional MPM lines MM05 (Relan et al, 2013), VMC23 (Kryeziu et al, 2013) and SPC111 (Schmitter et al, 1992) and the normal mesothelial line LP9 (Wu et al, 1982) were described previously.”
BackgroundmiR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma
Williams, M., Kirschner, M. B., Cheng, Y. Y., Hanh, J., Weiss, J., Amaro-Mugridge, N. B., Wright, C. M., Linton, A., Kao, S., Edelman, J. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4346 · Cited by 90
“MM05 [59], VMC23 [60], P31 [61], SPC111 and SPC212 [62] were described previously.”
Hillegass, J. M., Shukla, A., Lathrop, S. A., MacPherson, M. B., Beuschel, S. L., Butnor, K. J., Testa, J. R., Pass, H. I., Carbone, M., Steele, C., et al. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05554.x · Cited by 79
Fitzpatrick, D. R., Peroni, D. J., & Bielefeldt-Ohmann, H. (1995) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.12.5.7742009 · Cited by 79
Belyanskaya, L. L., Marti, T. M., Hopkins-Donaldson, S., Kurtz, S., Felley‐Bosco, E., & Stahel, R. A. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-66 · Cited by 76
“Results Expression of TRAIL receptors in MPM cell lines or primary cultures The expression of the four membrane-bound TRAILreceptors was analyzed in a large panel of commercially available and well-established MPM cells lines obtained from human biopsies or pleural effusions [24,25].”
BackgroundMethodSelf-citationHopkins-Donaldson, S., Cathomas, R. L., Simões‐Wüst, A. P., Kurtz, S., Belyanskya, L., Stahel, R. A., & Zangemeister‐Wittke, U. (2003) · International Journal of Cancer · doi:10.1002/ijc.11209 · Cited by 76
Self-citationKlominek, J., Baskin, B., Liu, Z., & Hauzenberger, D. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980413)76:2<240::aid-ijc12>3.0.co;2-g · Cited by 75
(1994) · PubMed · Cited by 65
Tumor-associated macrophages in thoracic malignancies
Lievense, L. A., Bezemer, K., Aerts, J. G. J. V., & Hegmans, J. P. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.02.017 · Cited by 65
de Lara, P. T., Cecconi, V., Hiltbrunner, S., Yagita∥, H., Friess, M., Bode, B., Opitz, I., Vrugt, B., Weder, W., Stolzmann, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1231 · Cited by 63
“ZL55 and SPC111 were generated in our laboratory (23) and MSTO-211H (24) was obtained from ATCC.”
MethodSelf-citationExpression and activity of matrix metalloproteases in human malignant mesothelioma cell lines
Liu, Z., Ivanoff, A., & Klominek, J. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(200002)9999:9999<::aid-ijc1102>3.0.co;2-y · Cited by 62
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma
Sandberg, A. A., & Bridge, J. A. (2001) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00432-0 · Cited by 58
Lü, C., Sheehan, C., Rak, J. W., Chambers, C. A., Hozumi, N., & Kerbel, R. S. (1996) · PubMed · Cited by 58
Yom, S. S., Busch, T. M., Friedberg, J. S., Wileyto, E. P., Smith, D., GLATSTEIN, E. J., & Hahn, S. M. (2003) · Photochemistry and Photobiology · doi:10.1562/0031-8655(2003)0780075esclim2.0.co2 · Cited by 57
Schürch, C. M., Forster, S., Bruehl, F. K., Yang, S. H.-Y., Felley‐Bosco, E., & Hewer, E. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373235 · Cited by 57
Malignant Pleural Mesothelioma
Ho, L., David, S. J., & Skarin, A. T. (2001) · Cancer treatment and research · doi:10.1007/978-1-4615-1589-0_13 · Cited by 56
Chemotaxis and chemokinesis of malignant mesothelioma cells to multiple growth factors.
Liu, Z., & Klominek, J. (2004) · PubMed · Cited by 54
p53-Induced Apoptosis Occurs in the Absence of p14ARF in Malignant Pleural Mesothelioma
Hopkins-Donaldson, S., Belyanskaya, A. L., Simões‐Wüst, A. P., Sigrist, B., Kurtz, S., Zangemeister‐Wittke, U., & Stahel, R. A. (2006) · Neoplasia · doi:10.1593/neo.06148 · Cited by 54
“Primary MPM cultures were derived from MPM pleural effusions, as described previously [18], and were characterized by the positive staining of cells with antibodies specific for calretinin.”
MethodSelf-citationInterleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon ? immunotherapy
Bielefeldt-Ohmann, H., Marzo, A. L., Himbeck, R. P., Jarnicki, A. G., Robinson, B. W. S., & Fitzpatrick, D. R. (1995) · Cancer Immunology Immunotherapy · doi:10.1007/bf01519898 · Cited by 52
“A role for IL-6 in mesothelioma-associated thrombocytosis has previously been suggested [ 30 ], whereas it has not yet been implicated in the, probably more important [23], symptoms such as fever and cachexia.”
BackgroundInfluentialBhattacharya, S. S., Thirusangu, P., Jin, L., Roy, D., Jung, D., Xiao, Y., Staub, J. K., Roy, B., Molina, J. R., & Shridhar, V. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1916-3 · Cited by 52
Proliferation of Human Non–Small-Cell Lung Cancer Cell Lines: Role of Interleukin-6
Bihl, M., Tamm, M., Nauck, M., Wieland, H., Perruchoud, A. P., & Roth, M. (1998) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.19.4.3247 · Cited by 46
“Enhanced synthesis of IL-6 has been reported in cells of renal-cell carcinoma (22), ovarian carcinoma (23), pleural mesothelioma ( 24 ), parotidgland adenoma (25), pheochromocytoma (26), and glioblastoma (27).”
BackgroundKlominek, J., Baskin, B., & Hauzenberger, D. (1998) · Clinical & Experimental Metastasis · doi:10.1023/a:1006542301794 · Cited by 47
“The following cell lines were used: ZL5 (generously provided by Dr Schmitter [ 34 ,35]) and M9K, M10K, M14K, M28K (generously provided by Dr Linnainmaa [36]).”
MethodKlominek, J., Sumitran‐Karuppan, S., & Hauzenberger, D. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970917)72:6<1034::aid-ijc19>3.0.co;2-4 · Cited by 45
Opitz, I., Sigrist, B., Hillinger, S., Lardinois, D., Stahel, R. A., Weder, W., & Hopkins-Donaldson, S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.01.024 · Cited by 44
Self-citationKoh, E., Iizasa, T., Yamaji, H., Sekine, Y., Hiroshima, K., Yoshino, I., & Fujisawa, T. (2012) · International Journal of Surgical Pathology · doi:10.1177/1066896911436274 · Cited by 43
Schmid, H., Schmitter, D., Blum, P., Miller, M., & Vonderschmitt, D. J. (1995) · Electrophoresis · doi:10.1002/elps.11501601322 · Cited by 43
Self-citationMolecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of Mesothelioma
Røe, O. D., Szulkin, A., Anderssen, E., Flatberg, A., Sandeck, H., Amundsen, T., Erlandsen, S. E., Dobra, K., & Sundstrøm, S. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040521 · Cited by 41
“Silencing of NT5C was performed with two MM cell lines, the sarcomatoid ZL-34 (kindly provided by Julius Klominek) [16] and the epithelioid M-14-K (kindly provided by K.”
MethodMórocz, I. Á., Schmitter, D., Lauber, B. A., & Stahel, R. A. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.410 · Cited by 40
Self-citationDirix, L. Y., van Meerbeeck, J. P., Schrijvers, D. M., Corthouts, B., Prové, A., Marck, E. V., Vermeire, P. A., & van Oosterom, A. T. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058941 · Cited by 40
Fiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V. (2023) · Cells · doi:10.3390/cells12162048 · Cited by 39
“High levels of IL-6 have been also revealed in patients’ pleural fluids [47].”
BackgroundInfluentialOien, D. B., Garay, T., Eckstein, S., & CHIEN, J. R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00970 · Cited by 40
“MPM cells lines used were SPC111, VMC14, VMC31, M38K, VMC40, Meso53, SPC212, and P31 (Marklund et al., 1982; Pelin-Enlund et al., 1990; Schmitter et al., 1992; Janson et al., 2008; Garay et al., 2013; Schelch et al., 2014; Hoda et al., 2016).”
MethodSzulkin, A., Ötvös, R. H.-G., Hillerdal, C.-O., Celep, A., Yousef-Fadhel, E., Skribek, H., Hjerpe, A., Székely, L., & Dobra, K. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-709 · Cited by 39
“MM cell lines: STAV-AB, STAV-FCS and ZL-34 cells were kindly provided by Julius Klominek [32,33].”
MethodPleural mesothelioma side populations have a precursor phenotype
Frei, C., Opitz, I., Soltermann, A., Fischer, B., Moura, U., Rehrauer, H., Weder, W., Stahel, R. A., & Felley‐Bosco, E. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr127 · Cited by 39
Self-citationde Morales, J. R., Vélez, D., & Subiza, J. L. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00119-8 · Cited by 39
The role of interleukin-6 in malignant mesothelioma.
Rahim, S. N. A., Ho, G., & Coward, J. I. G. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.07.01 · Cited by 38
“have previously concluded that IL-6 was not an autocrine growth factor as addition of rhIL-6 to MM cell lines did not induce DNA synthesis in the cells (54).”
BackgroundFischer, B., Frei, C., Moura, U., Stahel, R. A., & Felley‐Bosco, E. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.07.005 · Cited by 38
Self-citationMalignant pleural mesothelioma
Pass, H. I., & Pogrebniak, H. W. (1993) · Current Problems in Surgery · doi:10.1016/0011-3840(93)90029-g · Cited by 38
Biomarkers for Malignant Pleural Mesothelioma—A Novel View on Inflammation
Vogl, M., Rosenmayr, A., Bohanes, T., Scheed, A., Brndiar, M., Stubenberger, E., & Ghanim, B. (2021) · Cancers · doi:10.3390/cancers13040658 · Cited by 37
Burt, B. M., Bader, A., Winter, D. G., Rodig, S. J., Bueno, R., & Sugarbaker, D. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1808 · Cited by 35
Proteomic surfaceome analysis of mesothelioma
Ziegler, A., Cerciello, F., Bigosch, C., Bausch‐Fluck, D., Felley‐Bosco, E., Ossola, R., Soltermann, A., Stahel, R. A., & Wollscheid, B. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.07.009 · Cited by 35
Self-citationKato, N., Yasukawa, K., Onozuka, T., & KIMURA, K. M. (1999) · The Journal of Dermatology · doi:10.1111/j.1346-8138.1999.tb03487.x · Cited by 34
Cordier, L., Valeyrie, L., Fernandez, N. C., Opolon, P., Sabourin, J., Maubec, E., Roy, P. L., Kane, A. B., Legrand, A., Abina, A. M., et al. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700594 · Cited by 33
Upham, J. W., Garlepp, M. J., Musk, A. W., & Robinson, B. W. S. (1995) · Thorax · doi:10.1136/thx.50.8.887 · Cited by 33
Inflammation in malignant mesothelioma - friend or foe?
Linton, A., van Zandwijk, N., Reid, G., Clarke, S. J., Cao, C. Q., & Kao, S. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2225-319x.2012.10.02 · Cited by 32
“It has been shown that mesothelioma cells and cell lines produce IL-6 (44-46), and a clinical study of 25 patients with MPM demonstrated that IL-6 present in pleural fluid could leak into the systemic circulation, thereby inducing clinical inflammatory reaction reactions (47).”
BackgroundMutsaers, S. E., Pixley, F. J., Prêle, C. M., & Hoyne, G. F. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.04.005 · Cited by 31
Use of preclinical models for malignant pleural mesothelioma
Shamseddin, M., Obacz, J., Garnett, M. J., Rintoul, R. C., Francies, H. E., & Marciniak, S. J. (2021) · Thorax · doi:10.1136/thoraxjnl-2020-216602 · Cited by 32
Hillegass, J., Shukla, A., MacPherson, M. B., Bond, J. P., Steele, C. H., & Mossman, B. T. (2010) · Journal of Toxicology and Environmental Health · doi:10.1080/15287390903486568 · Cited by 31
“G-CSF is secreted from a number of different cell types and was shown to be expressed in normal human mesothelial cells and human MM cells in vitro (Demetri et al., 1989; Schmitter et al., 1992).”
BackgroundPKC-δ/PKC-α activity balance regulates the lethal effects of cisplatin
Muscella, A., Vetrugno, C., Antonaci, G., Cossa, L. G., & Marsigliante, S. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.08.103 · Cited by 30
Growth-factor-dependent migration of human lung-cancer cells
Bredin, C. G., Liu, Z., Hauzenberger, D., & Klominek, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990730)82:3<338::aid-ijc6>3.0.co;2-y · Cited by 30
Shi, Y., Felley‐Bosco, E., Marti, T. M., & Stahel, R. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045354 · Cited by 29
“The lovastatin-mediated protective effect seemed specific for normal cells, since none of the tested cancer cell lines, human mesothelioma ZL55, human breast cancer MCF-7 and human lung adenocarcinoma A549, was protected (Figure 2A).”
BackgroundSelf-citationMalignant pleural mesothelioma
Hoogsteden, H. C., Langerak, A. W., van der Kwast, T., Versnel, M. A., & van Gelder, T. (1997) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(96)00231-4 · Cited by 28
Opitz, I., Lardinois, D., Arni, S., Hillinger, S., VOGT, P. R., Odermatt, B., Rousson, V., & Weder, W. (2007) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2007.01.047 · Cited by 28
“Mesothelioma is reportedly an IL-6-secreting tumour [23,24].”
Expression of cytokines and their receptors by psoriatic fibroblasts I. Altered IL-6 synthesis
Debets, R., Hegmans, J. P., Deleuran, M., Hooft, S., Benner, R., & Prens, E. P. (1996) · Cytokine · doi:10.1006/cyto.1996.0010 · Cited by 28
In vitro and in vivo studies of mesothelioma
Pass, H. I., & Mew, D. (1996) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240630509 · Cited by 26
Cheng, X., & Lopez, D. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.6.2735 · Cited by 26
Favoni, R. E., Pattarozzi, A., Casto, M., Barbieri, F., Gatti, M., Paleari, L., Bajetto, A., Porcile, C., Gaudino, G., Mutti, L., et al. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791054130 · Cited by 25
“Stahel (University of Zurich, Switzerland) [27].”
BackgroundKao, S. C.-H., Kirschner, M. B., Cooper, W. A., Tran, T., Burgers, S. J. A., Wright, C. M., Korse, T., van den Broek, D. A., Edelman, J. J., Vallely, M. P., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.470 · Cited by 25
“In addition, the previously described MPM lines MM05 (Relan et al, 2013), VMC23 (Kryeziu et al, 2013) and SPC111 (Schmitter et al, 1992) and the mesothelial line LP9 (Wu et al, 1982) were included.”
BackgroundWörthmüller, J., Blum, W., Pecze, L., Salicio, V., & Schwaller, B. (2018) · Oncotarget · doi:10.18632/oncotarget.26332 · Cited by 25
“Human mesothelioma cell lines SPC111, ZL5, ZL55, SPC212 and ZL34, were obtained from the University Hospital of Zurich (Switzerland) [50].”
BackgroundFavoni, R. E., & Florio, T. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.03.011 · Cited by 25
Liu, Z., & Klominek, J. (2004) · Neoplasia · doi:10.1593/neo.04271 · Cited by 25
“Three human malignant mesothelioma cell lines were used: M14K (epithelial type), ZL34 (fibrous type), and SPC212 (mixed type) [37,39].”
MethodKimura, N., Ogasawara, T., Asonuma, S., Hama, H., Sawai, T., & Toyota, T. (2004) · Modern Pathology · doi:10.1038/modpathol.3800245 · Cited by 23
Malignant Pleural Mesothelioma Produces Functional Granulocyte-Colony Stimulating Factor
Kasuga, I., Ishizuka, S., Minemura, K., Utsumi, K., Ohyashiki, K., & Serizawa, H. (2001) · CHEST Journal · doi:10.1378/chest.119.3.981 · Cited by 23
Evidence for a common mutation in hereditary pancreatitis
Bell, S. M., Bennett, C., MARKHAM, A. F., & Lench, N. (1998) · Molecular Pathology · doi:10.1136/mp.51.2.115 · Cited by 23
Production of granulocyte colony-stimulating factor by malignant mesothelioma
Rikimaru, T., Ichikawa, Y., Ogawa, Y., 樋口, 栄., Kinosita, M., Oizumi, K., & Shima, I. (1995) · European Respiratory Journal · doi:10.1183/09031936.95.08010183 · Cited by 22
Judge, S. J., Thomas, P., Govindarajan, V., Sharma, P., & Loggie, B. W. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4965-6 · Cited by 21
“inflammation and cancer,(19) and findings have previously shown IL-6 to be expressed by several mesothelioma cell lines of pleural origin.(20) The influence of IL-6 in complex immunologic signaling is vast and extends beyond its established pro-inflammatory role.”
BackgroundHäner, K., Henzi, T., Pfefferli, M., Künzli, E., Salicio, V., & Schwaller, B. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22429 · Cited by 21
Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma
Greillier, L., Tounsi, A., Berenguer‐Daizé, C., Dussault, N., Delfino, C., Benyahia, Z., Cayol, M., Mabrouk, K., Garcia, S., Martin, P., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.004 · Cited by 20
Szulkin, A., Nilsonne, G., Mundt, F., Wasik, A. M., Souri, P., Hjerpe, A., & Dobra, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065903 · Cited by 20
“MM cell lines: STAV-AB, STAV-FCS and ZL-34 cells were kindly provided by Julius Klominek [34,35].”
MethodDoré, P., Lelièvre, E., Morel, F., Brizard, A., Fourcin, M., Clément, C., Ingrand, P., Daneski, L., Gascan, H., Wijdenes, J., et al. (1997) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1997.d01-889.x · Cited by 20
Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis
Dadgar, N., Sherry, C., Zimmerman, J., Park, H., Lewis, C. M., Donnenberg, A. D., Zaidi, A. H., Fan, Y., Xiao, K., Bartlett, D. L., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05205-8 · Cited by 20
“Although there has been only recent interest in IL-6 pathobiology in malignant peritoneal mesothelioma (MPM), IL-6 has long been suspected to contribute to pathophysiology of pleural malignant mesothelioma (MM) [235, 236].”
BackgroundTriozzi, P. L., Aldrich, W. A., Allen, K. O., Lima, J., Shaw, D. R., & Strong, T. V. (2004) · International Journal of Cancer · doi:10.1002/ijc.20574 · Cited by 19
Dowdall, J. F., Winter, D. C., Andrews, E., Laug, W. E., Wang, J. H., & Redmond, H. P. (2002) · Journal of Surgical Research · doi:10.1006/jsre.2001.6222 · Cited by 19
Ziegler, A., Seemayer, C. A., Hinterberger, M., VOGT, P. R., Bigosch, C., Gautschi, O. P., Tornillo, L., Betticher, D. C., Moch, H., & Stahel, R. A. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.03.025 · Cited by 19
Self-citationJAGIRDAR, R. M., Papazoglou, E. D., Pitaraki, E., Kouliou, O. A., Rouka, E. C., Giannakou, L., Giannopoulos, S., Sinis, S. I., Hatzoglou, C., Gourgoulianis, K. I., et al. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13446 · Cited by 17
Blum, W., Henzi, T., Pecze, L., Diep, K.-L., Bochet, C. G., & Schwaller, B. (2019) · Oncotarget · doi:10.18632/oncotarget.27341 · Cited by 17
“On average, epithelioid MM- Oncotarget6946www.oncotarget.com derived cells (H28, ZL55, JL-1, H226) showed a slightly higher sensitivity to FCF than most MM cells derived from biphasic MM (MSTO-211H, SPC111, SPC212) or the sarcomatoid MM-derived ZL34 cells.”
MethodNew chemotherapeutics in malignant mesothelioma: effects on cell growth and IL-6 production
McLaren, B. R., Robinson, B. W. S., & Lake, R. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051026 · Cited by 17
“IL-6 is found in the pleural ̄uid of patients [16] and in the supernatants of both human [22] and murine MM cell lines [1].”
BackgroundStam, Swaak, Kruit, Stoter, & Eggermont (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.00632.x · Cited by 17
Potential for cytokine therapy of malignant mesothelioma
Fitzpatrick, D. R., Manning, L. S., Musk, A. W., Robinson, B. W. S., & Bielefeldt‐Ohmann, H. (1995) · Cancer Treatment Reviews · doi:10.1016/0305-7372(95)90004-7 · Cited by 16
Identification ofcis-andtrans-acting elements regulating calretinin expression in mesothelioma cells
Kresoja‐Rakic, J., Kapaklikaya, E. L., Ziltener, G., Dalcher, D., Santoro, R., Christensen, B. C., Johnson, K. C., Schwaller, B., Weder, W., Stahel, R. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7114 · Cited by 15
“The following mesothelioma cell lines have been used: ZL55, ZL5, ZL34 and SPC111 from our laboratory [45]; NCI-H226, MSTO-211H, MeT5A [46] were obtained from ATCC; ACC-MESO-4 [47] were obtained from Riken BRC; and MERO-82, MERO-83, MERO-84 [48] and ONE58 [49] were obtained from the European Collection of Cell Cultures.”
MethodSelf-citationMuscella, A., Vetrugno, C., Cossa, L. G., Antonaci, G., Nuccio, F. D., Pascali, S. A. D., Fanizzi, F. P., & Marsigliante, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165154 · Cited by 15
Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma
Kresoja‐Rakic, J., Sulemani, M., Kirschner, M. B., Ronner, M., Reid, G., Kao, S., Schwaller, B., Weder, W., Stahel, R. A., & Felley‐Bosco, E. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00070 · Cited by 15
“Both ZL55 and SPC111 cell lines were established in our lab (Schmitter et al., 1992) whereas ONE58 was obtained from the European Collection of Cell Cultures (Salisbury, United Kingdom; Manning et al., 1991).”
BackgroundSelf-citationAutocrine Growth by Granulocyte Colony-Stimulating Factor in Malignant Mesothelioma
Nishimura, M., Itoh, K., Ito, K., Yanada, M., Terauchi, K., Fushiki, S., & Shimada, J. (2006) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2006.02.009 · Cited by 15
Interleukin 6-producing malignant mesothelioma
Motoyama, T., Honma, T., Watanabe, H., 本間, 滋., Kumanishi, T., & Abe, S. (1993) · Virchows Archiv B Cell Pathology Including Molecular Pathology · doi:10.1007/bf02915136 · Cited by 15
“Some investigators emphasize that IL-6 production is a common feature in mesothelioma cell lines ( Schmitter et al. 1992 ).”
Background
Metadata
- Authors
- Schmitter, D., Lauber, B., Fagg, B., & Stahel, R. A.
- Affiliations
- University Hospital Zurich (CH)
- Sandoz Group AG (Switzerland) (CH)
- Corresponding author
- Stahel, Rolf A.
- ORCID
- Stahel, Rolf A.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1992-05-08
- Volume
- 51
- Issue
- 2
- Pages
- 296-301
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2008766290
- Cited by
- 133
- References
- 27
- Citations by year
- 2024: 3 · 2023: 1 · 2021: 2 · 2020: 3 · 2019: 5 · 2018: 8 · 2017: 3 · 2016: 4 · 2015: 5 · 2014: 6 · 2013: 2 · 2012: 8
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- China Aerospace Science and Technology Corporation
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- pleural mesothelioma, hematopoietic growth factors, interleukin-6, GM-CSF, granulocyte colony-stimulating factor, conditioned medium, colony-stimulating activity, mitogenic activity, autocrine growth factor, paraneoplastic syndrome, thrombocytosis, mesothelial cells, cancer cell lines
- MeSH terms
- Humans, Mesothelioma, Pleural Neoplasms, Tumor Cells, Cultured, Tumor Stem Cell Assay, Interleukin-6, Granulocyte-Macrophage Colony-Stimulating Factor, Granulocyte Colony-Stimulating Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.